<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   The dyschromatoses
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       The dyschromatoses
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        The dyschromatoses
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michihiro Kono, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L Hand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H384754652">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dyschromatoses are a group of rare, inherited, pigmentary disorders characterized by the development during infancy or childhood of numerous, irregular, hyperpigmented and hypopigmented macules approximately 5 mm in diameter [
         <a href="#rid1">
          1
         </a>
         ]. Dyschromatosis symmetrica hereditaria (DSH; MIM #127400) and dyschromatosis universalis hereditaria (DUH; DUH1 [MIM #127500], DUH2 [MIM #612715], DUH3 [MIM #615402]), which are the two most common dyschromatoses, were first reported and most commonly occur in Japan.
        </p>
        <p>
         This topic will discuss the clinical manifestations, diagnosis, and treatment of DSH and DUH. Other congenital and inherited hyperpigmentation disorders and the acquired hyperpigmentation disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">
          "Acquired hyperpigmentation disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H61747388">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiologic data on the inherited dyschromatoses are limited. The prevalence of dyschromatosis symmetrica hereditaria (DSH) in Japan is estimated to be approximately 1.5 per 100,000 [
         <a href="#rid2">
          2
         </a>
         ]. The prevalence of dyschromatosis universalis hereditaria (DUH) is probably much lower than DSH prevalence. One study reported that approximately 1.9 and 0.3 per 100,000 dermatology consultations in Japan are related to DSH and DUH, respectively [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H384754658">
         <span class="h1">
          DYSCHROMATOSIS SYMMETRICA HEREDITARIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dyschromatosis symmetrica hereditaria (DSH), also called reticulate acropigmentation of Dohi, is an autosomal dominant disorder characterized by a mixture of hypopigmented and hyperpigmented macules approximately 5 mm in diameter on the dorsa of the hands and feet  (
         <a class="graphic graphic_picture graphicRef105809" href="/z/d/graphic/105809.html" rel="external">
          picture 1
         </a>
         ) and freckle-like macules on the face. First described by Toyama in 1910, DSH has been mainly reported in Japan and China [
         <a href="#rid4">
          4,5
         </a>
         ]. However, DSH has also been reported in patients from Korea [
         <a href="#rid6">
          6
         </a>
         ], Taiwan [
         <a href="#rid7">
          7
         </a>
         ], Thailand [
         <a href="#rid8">
          8
         </a>
         ], India [
         <a href="#rid9">
          9,10
         </a>
         ], Turkey [
         <a href="#rid11">
          11
         </a>
         ], Italy [
         <a href="#rid12">
          12
         </a>
         ], and the United Kingdom [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1470423">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         DSH (MIM #127400) is caused by variants in the adenosine deaminase acting on RNA1 gene (
         <em>
          ADAR1
         </em>
         ) at 1q21.3
         <em>
          ,
         </em>
         which encodes the RNA editing enzyme [
         <a href="#rid2">
          2
         </a>
         ]. DSH is inherited in an autosomal dominant manner with nearly complete penetrance but variable expressivity. Both familial and sporadic cases have been reported. More than 180 different variants throughout
         <em>
          ADAR1
         </em>
         have been described in patients with DSH [
         <a href="#rid14">
          14
         </a>
         ]. These variants, including nonsense, missense, frameshift, and splice-site variants, are thought to lead to
         <em>
          ADAR1
         </em>
         haploinsufficiency.
        </p>
        <p>
         A variant in the 5' untranslated region of
         <em>
          ADAR1
         </em>
         was described as pathogenic [
         <a href="#rid15">
          15
         </a>
         ]. The reduced translation of
         <em>
          ADAR1
         </em>
         was demonstrated to arise from this variant [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Biallelic variants in
         <em>
          ADAR1
         </em>
         cause Aicardi-Goutières syndrome 6 (AGS6; MIM #615010), a severe childhood autoimmune disease characterized by encephalitis and interferonopathy that mimics viral infection [
         <a href="#rid16">
          16
         </a>
         ]. However, DSH is generally not a feature of AGS.
        </p>
        <p>
         There are several reports of children with DSH, neurologic symptoms, and brain abnormalities (eg, calcifications or bilateral striatal necrosis) associated with compound heterozygous
         <em>
          ADAR1
         </em>
         variants [
         <a href="#rid10">
          10,17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1469335">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adenosine deaminase acting on RNA1 (ADAR1) is an RNA-editing enzyme that catalyzes the deamination of adenosine to inosine in double-stranded RNA substrates during post-transcription processing [
         <a href="#rid19">
          19
         </a>
         ]. Inosine acts as guanine during translation, resulting in codon alterations or alternative splicing sites that lead to functional changes in proteins [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         <em>
          ADAR1
         </em>
         has two isoforms of different sizes, regulated by different promoters: constitutively expressed ADAR1-p110 (110 kDa) and interferon-inducible ADAR1-p150 (150 kDa) [
         <a href="#rid21">
          21
         </a>
         ]. Regulated by different promoters, the two variants are thought to be involved in different cellular functions, including stem cell maintenance, protection against stress-induced apoptosis, and innate immune response [
         <a href="#rid22">
          22-25
         </a>
         ]. Studies indicate that the interferon-inducible ADAR1-p150 promoter is involved in the modulation of the response to several viral infections, including measles, influenza, hepatitis C, hepatitis D, lymphocytic choriomeningitis, and polyoma virus infection [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         Mutation analysis has shown mutations in the coding region only of the p150 isoform in DSH patients [
         <a href="#rid28">
          28
         </a>
         ]. This finding supports the hypothesis that DSH is caused by the p150 isoform of
         <em>
          ADAR1
         </em>
         , although the substrate gene edited by ADAR1 in the skin is unknown. Further studies are needed to clarify the mechanisms underlying the degeneration and/or dysfunction of melanocytes in DSH and its localization to the distal extremities and face, despite the ubiquitous expression of
         <em>
          ADAR1
         </em>
         [
         <a href="#rid22">
          22,29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1469243">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         DSH is characterized by a mixture of hypopigmented and hyperpigmented macules approximately 5 mm in diameter, distributed predominantly on the dorsal aspect of the hands and feet  (
         <a class="graphic graphic_picture graphicRef105809" href="/z/d/graphic/105809.html" rel="external">
          picture 1
         </a>
         ), but sometimes extending to the dorsal aspect of the extremities  (
         <a class="graphic graphic_picture graphicRef105810" href="/z/d/graphic/105810.html" rel="external">
          picture 2
         </a>
         ). In some patients, freckle-like macules or a mixture of hypopigmented and hyperpigmented macules develop on the face  (
         <a class="graphic graphic_picture graphicRef105811" href="/z/d/graphic/105811.html" rel="external">
          picture 3
         </a>
         ). The presence of facial lesions appears to be associated with greater severity of lesions on the extremities [
         <a href="#rid30">
          30
         </a>
         ]. Palms, soles, and mucosa are uninvolved.
        </p>
        <p>
         DSH commonly develops during infancy or early childhood [
         <a href="#rid31">
          31
         </a>
         ]. Lesions first appear before the age of six years in approximately 70 percent of cases [
         <a href="#rid32">
          32
         </a>
         ]. Lesions extend progressively during childhood, become stable before adolescence, and then persist for life [
         <a href="#rid31">
          31,33
         </a>
         ]. Skin findings are more pronounced after sun exposure, although patients do not show photosensitivity [
         <a href="#rid32">
          32,34,35
         </a>
         ].
        </p>
        <p>
         Lesions are asymptomatic and do not show telangiectasia, atrophy, or scale. Inter- and intrafamilial phenotypical variation has been reported [
         <a href="#rid36">
          36
         </a>
         ]. It is the author's experience that some parents may have only faint hypopigmented macules on the dorsa of the fingers, whereas their children have widespread macules over the extremities.
        </p>
        <p>
         DSH is, in most cases, an isolated disorder. However, there are rare reports of DSH in association with other disorders, including neurologic disorders [
         <a href="#rid10">
          10,17,33,37
         </a>
         ], pernio/chilblain [
         <a href="#rid38">
          38
         </a>
         ], psoriasis [
         <a href="#rid39">
          39
         </a>
         ], acral hypertrophy [
         <a href="#rid40">
          40
         </a>
         ], and depression [
         <a href="#rid41">
          41
         </a>
         ]. Some patients with DSH and neurologic symptoms may in fact have a variant of AGS associated with mutation in
         <em>
          ADAR1
         </em>
         [
         <a href="#rid16">
          16,18,33,37
         </a>
         ]. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H384754671">
         <span class="h2">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histopathologic examination of lesional skin shows little melanin in hypopigmented macules and increased melanin pigmentation in the basal layer of hyperpigmented lesions along with pigmentary incontinence [
         <a href="#rid7">
          7,36
         </a>
         ]. In the hypomelanotic areas, as well as in the surrounding normal skin, there is a decreased number of melanocytes; in the hyperchromic areas, melanocytes appear increased in size, with elongated and numerous dendrites, indicating active melanosome transfer to the keratinocytes [
         <a href="#rid7">
          7
         </a>
         ]. Electron microscopy studies have shown abnormalities in melanocytes in the hypomelanotic skin, including a decrease in number, fatty degeneration, vacuolization of cytoplasm, swollen mitochondria, and condensed, irregularly shaped nucleus [
         <a href="#rid7">
          7,36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H384754689">
         <span class="h1">
          DYSCHROMATOSIS UNIVERSALIS HEREDITARIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dyschromatosis universalis hereditaria (DUH) is a rare pigmentary genodermatosis characterized by hypopigmented and hyperpigmented macules involving the entire body surface. First described in 1933 by Ichikawa and Hiraga [
         <a href="#rid42">
          42
         </a>
         ], it predominantly occurs in patients from Japan [
         <a href="#rid43">
          43
         </a>
         ] but has also been reported in patients from India [
         <a href="#rid44">
          44,45
         </a>
         ], Bangladesh [
         <a href="#rid46">
          46
         </a>
         ], Saudi Arabia [
         <a href="#rid47">
          47,48
         </a>
         ], Nigeria [
         <a href="#rid49">
          49
         </a>
         ], and Tunisia [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1470200">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         DUH shows genetic heterogeneity. It is inherited in an autosomal dominant fashion with variable penetrance, but there are reports of autosomal recessive transmission [
         <a href="#rid47">
          47,51
         </a>
         ]. Cases due to de novo variants have also been described [
         <a href="#rid52">
          52
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DUH1
         </strong>
         – The locus for the autosomal dominant form (DUH1; MIM #127500) was initially mapped at chromosome 6q24-q25.2 in two Chinese families [
         <a href="#rid53">
          53
         </a>
         ]. Subsequently, heterozygous variants in the
         <em>
          SASH1
         </em>
         gene on chromosome 6q24 were detected in affected individuals from Chinese families with DUH1 [
         <a href="#rid54">
          54,55
         </a>
         ]. Other groups have reported that some cases with the lentiginous phenotype, but without hypopigmented, macular skin lesions, are associated with heterozygous
         <em>
          SASH1
         </em>
         variants [
         <a href="#rid56">
          56-58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Homozygous mutations in
         <em>
          SASH1
         </em>
         have been associated with CAPOK (cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma) syndrome (MIM #618373) in one Moroccan family cell [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DUH2
         </strong>
         – The locus for the autosomal recessive form DUH2 was mapped at chromosome 12q21-q23 in a consanguineous family from Saudi Arabia [
         <a href="#rid47">
          47,51
         </a>
         ]. However, a pathogenic gene variant for this subtype has not been identified.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DUH3
         </strong>
         – Genome-wide linkage analysis studies in two large, Chinese kindreds with multiple members affected over five generations indicated that DUH3 (MIM
         <em>
         </em>
         #615402) is caused by mutations in the adenosine triphosphate (ATP)-binding cassette subfamily B, member 6 gene (
         <em>
          ABCB6
         </em>
         ) at 2q35, encoding a transporter protein that regulates de novo porphyrin synthesis [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1470262">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         DUH is thought to be caused by a deficiency of melanin synthesis and/or melanosome sorting [
         <a href="#rid46">
          46,62,63
         </a>
         ]. The
         <em>
          ABCB6
         </em>
         gene is widely expressed in many tissues. In the skin, the ABCB6 protein is expressed in keratinocytes and melanocytes and has a diffuse cytoplasmic distribution, including the outer mitochondrial membrane, endoplasmic reticulum, Golgi apparatus, plasma membrane, and exosomes [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         In a study of mouse melanoma B16 cell line, the wild-type ABCB6 protein was distributed in an endosome-like pattern and was abundant in the dendrites, whereas the ABCB6 protein with the mutations found in DUH was retained in the Golgi body [
         <a href="#rid60">
          60
         </a>
         ]. These preliminary findings suggest that ABCB6 may be involved in the transfer of melanosome to keratinocytes.
        </p>
        <p>
         The function of
         <em>
          SASH1
         </em>
         is unknown. It has been suggested that
         <em>
          SASH1
         </em>
         may be a tumor suppressor gene involved in maintenance of cell and tissue homeostasis through a variety of cellular signaling pathways. In DUH, it may be involved in altered melanocyte migration and melanin synthesis [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H61746437">
         <span class="h2">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histologic examination of a skin biopsy shows, in DUH, a focal increase or decrease in the melanin content of the basal layer in hyper- and hypopigmented macules, respectively. Pigment incontinence is occasionally observed. An ultrastructural study demonstrated normal numbers of active melanocytes but different amounts of fully melanized melanosomes in hyperpigmented and hypopigmented macules [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1469621">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         DUH usually presents in the first year of life with asymptomatic, hyperpigmented and hypopigmented, irregular macules, similar to those seen in DSH, located mainly on the trunk but also on the face and extremities [
         <a href="#rid1">
          1
         </a>
         ]. Lesions on the face may resemble ephelides or lentigines. The palms, soles, and mucosal surfaces are usually spared but may be involved [
         <a href="#rid44">
          44,66
         </a>
         ]. Some patients may present with multiple lentigines in the absence of hypopigmented, macular skin lesions [
         <a href="#rid56">
          56-58
         </a>
         ].
        </p>
        <p>
         DUH usually occurs in isolation. However, there are reports of DUH associated with systemic complications, including short stature, deafness, epilepsy, and erythrocyte, platelet, and tryptophan metabolism abnormalities [
         <a href="#rid1">
          1,44,45,67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H384754720">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of inherited dyschromatosis is usually clinical. Histology is nonspecific and shows focal increase or decrease in melanin content of the basal layer in the hyperpigmented and hypopigmented macules, respectively.
        </p>
        <p>
         Although the individual macular lesions of dyschromatosis symmetrica hereditaria (DSH) and dyschromatosis universalis hereditaria (DUH) are indistinguishable on typical cases, differentiating DSH from DUH is usually not difficult based upon clinical findings, including lesion distribution and time of onset:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In DSH, lesions manifest during childhood and are typically limited to the distal extremities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In DUH, lesions appear in the first year of life on the trunk and then extend to the entire body surface.
        </p>
        <p>
        </p>
        <p>
         Genetic testing is not routinely performed; however, it may be helpful in difficult cases to differentiate DSH and DUH from each other and from other inherited disorders of pigmentation.
        </p>
        <p class="headingAnchor" id="H1736661970">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inherited and acquired pigmentary disorders that may be confused with DSH or DUH include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reticulate acropigmentation of Kitamura
         </strong>
         – Reticulate acropigmentation of Kitamura (RAK; MIM #615537) is a rare genodermatosis caused by mutations in the
         <em>
          ADAM10
         </em>
         gene, encoding A disintegrin and metalloproteinase domain-containing protein 10 [
         <a href="#rid68">
          68
         </a>
         ]. RAK is characterized by dot-like or reticulate, slightly depressed, sharply demarcated, hyperpigmented macules affecting the dorsa of the hands  (
         <a class="graphic graphic_picture graphicRef105812" href="/z/d/graphic/105812.html" rel="external">
          picture 4
         </a>
         ) and feet and palmoplantar pits [
         <a href="#rid69">
          69
         </a>
         ]. In contrast to DSH, hypopigmented macules are absent in RAK. (See
         <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">
          "Congenital and inherited hyperpigmentation disorders", section on 'Reticulate acropigmentation of Kitamura'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dowling-Degos disease
         </strong>
         – Dowling-Degos disease (DDD; MIM #179850, #607491, #615618) is a rare genodermatosis caused by mutations in the
         <em>
          KRT5
         </em>
         gene [
         <a href="#rid70">
          70
         </a>
         ], the
         <em>
          POFUT1
         </em>
         gene [
         <a href="#rid71">
          71
         </a>
         ], and the
         <em>
          POGLUT1
         </em>
         gene [
         <a href="#rid72">
          72
         </a>
         ]. DDD is characterized by dot-like or reticulate, hyperpigmented macules mainly affecting the flexures and major skin folds. However, a single report described a patient with DDD due to a heterozygous
         <em>
          POGLUT1
         </em>
         mutation who showed sharply demarcated, hyperpigmented macules mainly affecting the dorsa of the hands and feet  (
         <a class="graphic graphic_picture graphicRef122194" href="/z/d/graphic/122194.html" rel="external">
          picture 5
         </a>
         ) and sparing the flexor areas of the extremities [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Xeroderma pigmentosum
         </strong>
         – Xeroderma pigmentosum (XP) is a rare autosomal recessive disease caused by mutations in genes involved in nucleotide excision repair of carcinogen adducts induced by ultraviolet (UV) irradiation [
         <a href="#rid74">
          74
         </a>
         ]. XP is characterized by extreme sensitivity of the skin to sunlight, abnormal pigmentation, xerosis, telangiectasia, atrophy, and a high tendency to develop skin cancers at a very early age. Mild cases of XP or the early stage of XP in a child may be sometimes difficult to differentiate from DSH [
         <a href="#rid35">
          35
         </a>
         ]. Photosensitivity tests, cellular hypersensitivity to UV radiation, complementation studies and chromosomal breakage studies using the patient's fibroblasts, and genetic analyses can be performed for definite diagnosis [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3004.html" rel="external">
          "The genodermatoses: An overview", section on 'Xeroderma pigmentosum'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Amyloidosis cutis dyschromica
         </strong>
         – Amyloidosis cutis dyschromica is an exceedingly rare type of primary cutaneous amyloidosis characterized by reticular hyperpigmentation with hypopigmented macules distributed over nearly all of the body  (
         <a class="graphic graphic_picture graphicRef94996" href="/z/d/graphic/94996.html" rel="external">
          picture 6
         </a>
         ). Histologic examination of a skin biopsy shows hyperkeratosis, necrotic keratinocytes in the basal layer, and melanophages as well as amorphous eosinophilic material (amyloid) deposits in the upper dermis. (See
         <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">
          "Acquired hyperpigmentation disorders", section on 'Primary cutaneous amyloidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Exposure to chemicals that are toxic to melanocytes, such as diphenylcyclopropenone and monobenzyl ether of
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         , may cause patchy depigmentation that may mimic the dyschromatoses [
         <a href="#rid75">
          75
         </a>
         ]. History of exposure to these agents usually clarifies the diagnosis. Histologic examination of a skin biopsy shows absence of melanocytes in the hypopigmented areas.
        </p>
        <p class="headingAnchor" id="H384754726">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no effective treatments for the hereditary dyschromatoses. Because tanning emphasizes the contrast between hyperpigmented and hypopigmented spots, patients with dyschromatosis should adopt photoprotection measures, including sun avoidance and use of protective clothing and broad-spectrum sunscreens with a sun protection factor (SPF) of at least 30. There is a single case report of dyschromatosis symmetrica hereditaria (DSH) lesions successfully controlled by topical sunscreen [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         There is a single case report of treatment of DSH lesions using miniature punch grafting followed by excimer light therapy [
         <a href="#rid77">
          77
         </a>
         ]. The Q-switched alexandrite laser has been successfully used to remove facial and labial lentigines in a single patient with DUH [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1470585">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – The dyschromatoses are a group of rare, inherited, pigmentary disorders mainly reported in Japan and China and characterized by the presence of numerous, irregular, hyperpigmented and hypopigmented macules approximately 5 mm in diameter. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dyschromatosis symmetrica hereditaria
         </strong>
         – Dyschromatosis symmetrica hereditaria (DSH), also called reticulate acropigmentation of Dohi, is an autosomal dominant disorder caused by mutations in
         <em>
          ADAR1
         </em>
         gene, encoding the RNA editing enzyme
         <em>
         </em>
         adenosine deaminases acting on RNA1 (ADAR1). DSH develops during infancy or early childhood and is characterized by a mixture of hypopigmented and hyperpigmented macules approximately 5 mm in diameter on the dorsa of the hands and feet and freckle-like macules on the face  (
         <a class="graphic graphic_picture graphicRef94173" href="/z/d/graphic/94173.html" rel="external">
          picture 7
         </a>
         ). (See
         <a class="local">
          'Dyschromatosis symmetrica hereditaria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dyschromatosis universalis hereditaria
         </strong>
         – Dyschromatosis universalis hereditaria (DUH) is a rare pigmentary genodermatosis characterized by hypopigmented and hyperpigmented macules, which is the same as the lesion of DSH, involving the entire body surface. DUH is inherited in an autosomal dominant or recessive manner and shows genetic heterogeneity. DUH has been reported in association with short stature, deafness, epilepsy, and erythrocyte, platelet, and tryptophan metabolism abnormalities. (See
         <a class="local">
          'Dyschromatosis universalis hereditaria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis and differential diagnosis
         </strong>
         – The diagnosis of inherited dyschromatosis is usually clinical. Histology is nonspecific and shows focal increase or decrease in melanin content of the basal layer. Genetic testing is not routinely performed; however, it may be helpful in difficult cases to differentiate DSH and DUH from each other and from other inherited or acquired disorders presenting with dyspigmentation, such as reticulate acropigmentation of Kitamura (RAK), Dowling-Degos disease (DDD), xeroderma pigmentosum (XP), and amyloidosis cutis dyschromica. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – There are no effective treatments for the inherited dyschromatoses. Photoprotection measures, including sun avoidance and use of protective clothing and broad-spectrum sunscreens with a sun protection factor (SPF) of at least 30 may be helpful to avoid contrast enhancement between hyperpigmented and hypopigmented macules. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Urabe K, Hori Y. Dyschromatosis. Semin Cutan Med Surg 1997; 16:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyamura Y, Suzuki T, Kono M, et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am J Hum Genet 2003; 73:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukai K, Oiso N, Kawaguchi M, et al. Guidelines for the diagnosis and treatment of oculo-cutaneous albinism in Japan (in Japanese). Jpn J Dermatol 2014; 124:1897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toyama I. An unknown disorder of hyperpigmentation (in Japanese). Jpn J Dermatol Urol 1910; 10:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toyama I. Dyschromatosis symmetrica hereditaria (in Japanese). Jpn J Dermatol Urol 1929; 29:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim NI, Park SA, Youn JI. Dyschromatosis symmetrica hereditaria affecting two families. Korean J Dermatol 1980; 18:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheu HM, Yu HS. Dyschromatosis symmetrica hereditaria--a histochemical and ultrastructural study. Taiwan Yi Xue Hui Za Zhi 1985; 84:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantaputra PN, Chinadet W, Ohazama A, Kono M. Dyschromatosis symmetrica hereditaria with long hair on the forearms, hypo/hyperpigmented hair, and dental anomalies: report of a novel ADAR1 mutation. Am J Med Genet A 2012; 158A:2258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhar S, Malakar S. Acropigmentation of Dohi in a 12-year-old boy. Pediatr Dermatol 1998; 15:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono M, Suganuma M, Dutta A, et al. Bilateral striatal necrosis and dyschromatosis symmetrica hereditaria: A-I editing efficiency of ADAR1 mutants and phenotype expression. Br J Dermatol 2018; 179:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilen N, Aktürk AŞ, Kawaguchi M, et al. Dyschromatosis symmetrica hereditaria: a case report from Turkey, a new association and a novel gene mutation. J Dermatol 2012; 39:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patrizi A, Manneschi V, Pini A, et al. Dyschromatosis symmetrica hereditaria associated with idiopathic torsion dystonia. A case report. Acta Derm Venereol 1994; 74:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostlere LS, Ratnavel RC, Lawlor F, et al. Reticulate acropigmentation of Dohi. Clin Exp Dermatol 1995; 20:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono M, Akiyama M. Dyschromatosis symmetrica hereditaria and reticulate acropigmentation of Kitamura: An update. J Dermatol Sci 2019; 93:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suganuma M, Kono M, Yamanaka M, Akiyama M. Pathogenesis of a variant in the 5' untranslated region of ADAR1 in dyschromatosis symmetrica hereditaria. Pigment Cell Melanoma Res 2020; 33:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice GI, Kasher PR, Forte GM, et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet 2012; 44:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono M, Matsumoto F, Suzuki Y, et al. Dyschromatosis Symmetrica Hereditaria and Aicardi-Goutières Syndrome 6 Are Phenotypic Variants Caused by ADAR1 Mutations. J Invest Dermatol 2016; 136:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanke S, Himadri H, Yadav J, et al. Pigmentary anomalies and neurologic symptoms in two siblings. Pediatr Dermatol 2021; 38:e16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bass BL, Weintraub H. An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 1988; 55:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rueter SM, Dawson TR, Emeson RB. Regulation of alternative splicing by RNA editing. Nature 1999; 399:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson JB, Samuel CE. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol 1995; 15:5376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Miyakoda M, Yang W, et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem 2004; 279:4952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qiu W, Wang X, Buchanan M, et al. ADAR1 is essential for intestinal homeostasis and stem cell maintenance. Cell Death Dis 2013; 4:e599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartner JC, Walkley CR, Lu J, Orkin SH. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol 2009; 10:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George CX, John L, Samuel CE. An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1). J Interferon Cytokine Res 2014; 34:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson JB, Thomis DC, Hans SL, Samuel CE. Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology 1995; 210:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuel CE. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 2011; 411:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki N, Suzuki T, Inagaki K, et al. Ten novel mutations of the ADAR1 gene in Japanese patients with dyschromatosis symmetrica hereditaria. J Invest Dermatol 2007; 127:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi T, Kono M, Suganuma M, et al. Analysis of genotype/phenotype correlations in Japanese patients with dyschromatosis symmetrica hereditaria. Nagoya J Med Sci 2018; 80:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomita Y, Suzuki T. Genetics of pigmentary disorders. Am J Med Genet C Semin Med Genet 2004; 131C:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oyama M, Shimizu H, Ohata Y, et al. Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi): report of a Japanese family with the condition and a literature review of 185 cases. Br J Dermatol 1999; 140:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondo T, Suzuki T, Ito S, et al. Dyschromatosis symmetrica hereditaria associated with neurological disorders. J Dermatol 2008; 35:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hou Y, Chen J, Gao M, et al. Five novel mutations of RNA-specific adenosine deaminase gene with dyschromatosis symmetrica hereditaria. Acta Derm Venereol 2007; 87:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishigori C, Miyachi Y, Takebe H, Imamura S. A case of xeroderma pigmentosum with clinical appearance of dyschromatosis symmetrica hereditaria. Pediatr Dermatol 1986; 3:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondo T, Suzuki T, Mitsuhashi Y, et al. Six novel mutations of the ADAR1 gene in patients with dyschromatosis symmetrica hereditaria: histological observation and comparison of genotypes and clinical phenotypes. J Dermatol 2008; 35:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tojo K, Sekijima Y, Suzuki T, et al. Dystonia, mental deterioration, and dyschromatosis symmetrica hereditaria in a family with ADAR1 mutation. Mov Disord 2006; 21:1510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono M, Suganuma M, Shimada T, et al. Dyschromatosis symmetrica hereditaria with chilblains due to a novel two-amino-acid deletion in the double-stranded RNA-binding domain of ADAR1. J Eur Acad Dermatol Venereol 2018; 32:e394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi BJ, Xue M, Liu Y, et al. First report of the coexistence of dyschromatosis symmetrica hereditaria and psoriasis: one novel TCT to A mutation in the double-RNA-specific adenosine deaminase gene. J Eur Acad Dermatol Venereol 2012; 26:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murata T, Yagi Y, Tanioka M, et al. Dyschromatosis symmetrica hereditaria with acral hypertrophy. Eur J Dermatol 2011; 21:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo S, Zheng Y, Ni H, et al. Novel clinical and molecular findings in Chinese families with dyschromatosis symmetrica hereditaria. J Dermatol 2012; 39:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichikawa T, Hiraga Y. A previously undescribed anomaly of pigmentation dyschromatosis universalis hereditaria. Jpn J Dermatol Urol 1933; 34:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SUENAGA M. Genetical studies on skin diseases. VII. Dyschromatosis universalis hereditaria in 5 generations. Tohoku J Exp Med 1952; 55:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udayashankar C, Nath AK. Dyschromatosis universalis hereditaria: a case report. Dermatol Online J 2011; 17:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethuraman G, Srinivas CR, D'Souza M, et al. Dyschromatosis universalis hereditaria. Clin Exp Dermatol 2002; 27:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nuber UA, Tinschert S, Mundlos S, Hauber I. Dyschromatosis universalis hereditaria: familial case and ultrastructural skin investigation. Am J Med Genet A 2004; 125A:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bukhari IA, El-Harith EA, Stuhrmann M. Dyschromatosis universalis hereditaria as an autosomal recessive disease in five members of one family. J Eur Acad Dermatol Venereol 2006; 20:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Hawsawi K, Al Aboud K, Ramesh V, Al Aboud D. Dyschromatosis universalis hereditaria: report of a case and review of the literature. Pediatr Dermatol 2002; 19:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yusuf SM, Mijinyawa MS, Maiyaki MB, Mohammed AZ. Dyschromatosis universalis hereditaria in a young Nigerian female. Int J Dermatol 2009; 48:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenani N, Ghariani N, Denguezli M, et al. Dyschromatosis universalis hereditaria: two cases. Dermatol Online J 2008; 14:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuhrmann M, Hennies HC, Bukhari IA, et al. Dyschromatosis universalis hereditaria: evidence for autosomal recessive inheritance and identification of a new locus on chromosome 12q21-q23. Clin Genet 2008; 73:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           An JM, Ko BJ, Cho MK, Whang KU. A Case of Sporadic Dyschromatosis Universalis Hereditaria. Ann Dermatol 2015; 27:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xing QH, Wang MT, Chen XD, et al. A gene locus responsible for dyschromatosis symmetrica hereditaria (DSH) maps to chromosome 6q24.2-q25.2. Am J Hum Genet 2003; 73:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou D, Wei Z, Kuang Z, et al. A novel P53/POMC/Gαs/SASH1 autoregulatory feedback loop activates mutated SASH1 to cause pathologic hyperpigmentation. J Cell Mol Med 2017; 21:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhong WL, Wang HJ, Lin ZM, Yang Y. Novel mutations in SASH1 associated with dyschromatosis universalis hereditaria. Indian J Dermatol Venereol Leprol 2019; 85:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shellman YG, Lambert KA, Brauweiler A, et al. SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype. J Invest Dermatol 2015; 135:3192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Zhang J, Li X, et al. A Novel De novo Mutation of the SASH1 Gene in a Chinese Family with Multiple Lentigines. Acta Derm Venereol 2017; 97:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Araki Y, Okamura K, Saito T, et al. Five novel mutations in SASH1 contribute to lentiginous phenotypes in Japanese families. Pigment Cell Melanoma Res 2021; 34:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Courcet JB, Elalaoui SC, Duplomb L, et al. Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma. Eur J Hum Genet 2015; 23:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang C, Li D, Zhang J, et al. Mutations in ABCB6 cause dyschromatosis universalis hereditaria. J Invest Dermatol 2013; 133:2221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu H, Li Y, Hung KK, et al. Genome-wide linkage, exome sequencing and functional analyses identify ABCB6 as the pathogenic gene of dyschromatosis universalis hereditaria. PLoS One 2014; 9:e87250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang G, Li CY, Gao TW, Liu YF. Dyschromatosis universalis hereditaria: two cases in a Chinese family. Clin Exp Dermatol 2005; 30:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim NS, Im S, Kim SC. Dyschromatosis universalis hereditaria: an electron microscopic examination. J Dermatol 1997; 24:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cui H, Guo S, He H, et al. SASH1 promotes melanin synthesis and migration via suppression of TGF-β1 secretion in melanocytes resulting in pathologic hyperpigmentation. Int J Biol Sci 2020; 16:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaufmann J, Franke FC, Sperlich A, et al. The emerging and diverse roles of the SLy/SASH1-protein family in health and disease-Overview of three multifunctional proteins. FASEB J 2021; 35:e21470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naveen KN, Dinesh US. Dyschromatosis universalis hereditaria with involvement of palms. Indian Dermatol Online J 2014; 5:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shono S, Toda K. Universal dyschromatosis associated with photosensitivity and neurosensory hearing defect. Arch Dermatol 1990; 126:1659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono M, Sugiura K, Suganuma M, et al. Whole-exome sequencing identifies ADAM10 mutations as a cause of reticulate acropigmentation of Kitamura, a clinical entity distinct from Dowling-Degos disease. Hum Mol Genet 2013; 22:3524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono M, Suganuma M, Takama H, et al. Dowling-Degos disease with mutations in POFUT1 is clinicopathologically distinct from reticulate acropigmentation of Kitamura. Br J Dermatol 2015; 173:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betz RC, Planko L, Eigelshoven S, et al. Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease. Am J Hum Genet 2006; 78:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li M, Cheng R, Liang J, et al. Mutations in POFUT1, encoding protein O-fucosyltransferase 1, cause generalized Dowling-Degos disease. Am J Hum Genet 2013; 92:895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basmanav FB, Oprisoreanu AM, Pasternack SM, et al. Mutations in POGLUT1, encoding protein O-glucosyltransferase 1, cause autosomal-dominant Dowling-Degos disease. Am J Hum Genet 2014; 94:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono M, Sawada M, Nakazawa Y, et al. A Japanese Case of Galli-Galli Disease due to a Previously Unreported POGLUT1 Mutation. Acta Derm Venereol 2019; 99:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol 2012; 132:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vachiramon V, Thadanipon K, Rattanakaemakorn P. Adult-onset dyschromatoses. Clin Exp Dermatol 2012; 37:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono M, Okamoto T, Takeichi T, et al. Dyschromatosis symmetrica hereditaria may be successfully controlled by topical sunscreen. Eur J Dermatol 2018; 28:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawakami T, Otaguchi R, Kyoya M, et al. Patient with dyschromatosis symmetrica hereditaria treated with miniature punch grafting, followed by excimer light therapy. J Dermatol 2013; 40:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nogita T, Mitsuhashi Y, Takeo C, Tsuboi R. Removal of facial and labial lentigines in dyschromatosis universalis hereditaria with a Q-switched alexandrite laser. J Am Acad Dermatol 2011; 65:e61.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15525 Version 12.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9125769" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Dyschromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12916015" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Guidelines for the diagnosis and treatment of oculo-cutaneous albinism in Japan (in Japanese)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : An unknown disorder of hyperpigmentation (in Japanese)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Dyschromatosis symmetrica hereditaria (in Japanese)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Dyschromatosis symmetrica hereditaria affecting two families
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3925074" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Dyschromatosis symmetrica hereditaria--a histochemical and ultrastructural study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22821605" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Dyschromatosis symmetrica hereditaria with long hair on the forearms, hypo/hyperpigmented hair, and dental anomalies: report of a novel ADAR1 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9655327" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acropigmentation of Dohi in a 12-year-old boy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29603717" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Bilateral striatal necrosis and dyschromatosis symmetrica hereditaria: A-I editing efficiency of ADAR1 mutants and phenotype expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22594859" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Dyschromatosis symmetrica hereditaria: a case report from Turkey, a new association and a novel gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7911621" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Dyschromatosis symmetrica hereditaria associated with idiopathic torsion dystonia. A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8857341" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Reticulate acropigmentation of Dohi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30692041" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Dyschromatosis symmetrica hereditaria and reticulate acropigmentation of Kitamura: An update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31926050" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Pathogenesis of a variant in the 5' untranslated region of ADAR1 in dyschromatosis symmetrica hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23001123" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26802932" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Dyschromatosis Symmetrica Hereditaria and Aicardi-Goutières Syndrome 6 Are Phenotypic Variants Caused by ADAR1 Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37489631" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pigmentary anomalies and neurologic symptoms in two siblings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3203381" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : An unwinding activity that covalently modifies its double-stranded RNA substrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10331393" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Regulation of alternative splicing by RNA editing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7565688" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14613934" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23598411" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : ADAR1 is essential for intestinal homeostasis and stem cell maintenance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19060901" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24905200" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7618288" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21211811" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16917490" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Ten novel mutations of the ADAR1 gene in Japanese patients with dyschromatosis symmetrica hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11585785" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Antiviral actions of interferons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29915444" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Analysis of genotype/phenotype correlations in Japanese patients with dyschromatosis symmetrica hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15452859" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Genetics of pigmentary disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10233273" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi): report of a Japanese family with the condition and a literature review of 185 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19017046" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Dyschromatosis symmetrica hereditaria associated with neurological disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17225010" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Five novel mutations of RNA-specific adenosine deaminase gene with dyschromatosis symmetrica hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3809028" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A case of xeroderma pigmentosum with clinical appearance of dyschromatosis symmetrica hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18705826" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Six novel mutations of the ADAR1 gene in patients with dyschromatosis symmetrica hereditaria: histological observation and comparison of genotypes and clinical phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16817193" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Dystonia, mental deterioration, and dyschromatosis symmetrica hereditaria in a family with ADAR1 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29775506" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Dyschromatosis symmetrica hereditaria with chilblains due to a novel two-amino-acid deletion in the double-stranded RNA-binding domain of ADAR1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21564324" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : First report of the coexistence of dyschromatosis symmetrica hereditaria and psoriasis: one novel TCT to A mutation in the double-RNA-specific adenosine deaminase gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21840790" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Dyschromatosis symmetrica hereditaria with acral hypertrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22077581" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Novel clinical and molecular findings in Chinese families with dyschromatosis symmetrica hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A previously undescribed anomaly of pigmentation dyschromatosis universalis hereditaria
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14950856" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Genetical studies on skin diseases. VII. Dyschromatosis universalis hereditaria in 5 generations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21382285" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Dyschromatosis universalis hereditaria: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12372090" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Dyschromatosis universalis hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14994234" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Dyschromatosis universalis hereditaria: familial case and ultrastructural skin investigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16684309" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Dyschromatosis universalis hereditaria as an autosomal recessive disease in five members of one family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12437556" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Dyschromatosis universalis hereditaria: report of a case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19570083" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Dyschromatosis universalis hereditaria in a young Nigerian female.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18700119" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Dyschromatosis universalis hereditaria: two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18462451" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Dyschromatosis universalis hereditaria: evidence for autosomal recessive inheritance and identification of a new locus on chromosome 12q21-q23.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26273173" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A Case of Sporadic Dyschromatosis Universalis Hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12815562" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A gene locus responsible for dyschromatosis symmetrica hereditaria (DSH) maps to chromosome 6q24.2-q25.2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27885802" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A novel P53/POMC/Gαs/SASH1 autoregulatory feedback loop activates mutated SASH1 to cause pathologic hyperpigmentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29956681" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Novel mutations in SASH1 associated with dyschromatosis universalis hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26203640" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27840890" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A Novel De novo Mutation of the SASH1 Gene in a Chinese Family with Multiple Lentigines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32981204" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Five novel mutations in SASH1 contribute to lentiginous phenotypes in Japanese families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25315659" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23519333" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Mutations in ABCB6 cause dyschromatosis universalis hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24498303" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Genome-wide linkage, exome sequencing and functional analyses identify ABCB6 as the pathogenic gene of dyschromatosis universalis hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16045675" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Dyschromatosis universalis hereditaria: two cases in a Chinese family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9114612" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Dyschromatosis universalis hereditaria: an electron microscopic examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32174800" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : SASH1 promotes melanin synthesis and migration via suppression of TGF-β1 secretion in melanocytes resulting in pathologic hyperpigmentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33710696" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The emerging and diverse roles of the SLy/SASH1-protein family in health and disease-Overview of three multifunctional proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25165647" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Dyschromatosis universalis hereditaria with involvement of palms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2256700" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Universal dyschromatosis associated with photosensitivity and neurosensory hearing defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23666529" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Whole-exome sequencing identifies ADAM10 mutations as a cause of reticulate acropigmentation of Kitamura, a clinical entity distinct from Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25639155" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Dowling-Degos disease with mutations in POFUT1 is clinicopathologically distinct from reticulate acropigmentation of Kitamura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16465624" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23684010" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Mutations in POFUT1, encoding protein O-fucosyltransferase 1, cause generalized Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24387993" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Mutations in POGLUT1, encoding protein O-glucosyltransferase 1, cause autosomal-dominant Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30653241" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A Japanese Case of Galli-Galli Disease due to a Previously Unreported POGLUT1 Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22217736" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Shining a light on xeroderma pigmentosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22007646" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Adult-onset dyschromatoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30378542" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Dyschromatosis symmetrica hereditaria may be successfully controlled by topical sunscreen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23803141" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Patient with dyschromatosis symmetrica hereditaria treated with miniature punch grafting, followed by excimer light therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21763558" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Removal of facial and labial lentigines in dyschromatosis universalis hereditaria with a Q-switched alexandrite laser.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
